The global Systemic Lupus Erythematosus Drugs market was valued at $1.92 Million in 2017 and is forecast to grow at a modest XX.2 % CAGR between 2018 and 2025, culminating in 2025 global sales of $2.56 Billion.
Systemic lupus erythematosus (SLE) is an autoimmune disease in which the body’s immune system mistakenly attacks healthy tissue in many parts of the body. Sign and Symptoms may differ from individual to individual including painful and swollen joints, chest pain, fever, hair loss, mouth ulcers, feeling tired, swollen lymph nodes and a red rash on face.
Cause of Systemic lupus erythematosus (SLE) is not clear. However, it’s mix of genetic and environmental factors. Female sex hormone, sunlight, smoking and Vitamin D deficiency will further aggravate the symptom. There is different type of lupus erythematosus like discoid lupus erythematosus, neonatal lupus, and subacute cutaneous lupus erythematosus.
“Optimal Price Point (OPP) for Systemic Lupus Erythematosus Drugs”
Estimated Average product/ service cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model.
Due to the wide array of products available in the market, pricing, positioning, and sales channel optimization play a vital role in the success of a product. On an average, in the U.S., the Systemic Lupus Erythematosus drugs are available at USD xxx- USD xxxx. However, the high-end products are available at much higher prices. The prices in emerging countries and developed countries vary significantly due to the difference in purchasing power and availability of latest products.
Systemic Lupus Erythematosus Market by “Drugs Type”
We have segmented the Systemic Lupus Erythematosus treatment market into Immunosuppressants, Biologics, Antimalarials, NSAIDs, Corticosteroids and Intravenous immunoglobulins. Immunosuppressants seems to be the leading prescribed drugs in this category due to availability of low cost methotrexate. We are observing slow adaptation of biologic (Benlysta). However, Benlysta will uptake quickly and high recommendation for mild to moderate Systemic Lupus Erythematosus among KOL interviewed. Some physicians are also using rituximab as off level for the treatment of Systemic Lupus Erythematosus.
Systemic Lupus Erythematosus Market by “Route of Administration”
We have segmented the Systemic Lupus Erythematosus market by type of route of administration into Oral, Intravenous, Subcutaneous. We are observing newer biologic into immunotherapy shaping the Systemic Lupus Erythematosus. New upcoming treatments will be intravenous route of administration. Cost estimates for de novo drug discovery range from $500 million to $2 billion.
Systemic Lupus Erythematosus Market by “Distribution Channel”
We have segmented the market based on distribution channel as Hospitals, Drug Store, Specialty Pharmacy, E-Pharmacy. Majority of products channelized through hospitals. However, we are observing the increased role of specialized pharmacy and E-pharmacy in the distribution/ dispensation of treatment drugs. Patient education to increase compliance and Persistency plays a key role in the outcome. Many payors are linking reimbursement to the outcome.
North America accounted for the maximum revenue share of over 70% in 2017 due to increased patient number, lifestyle followed by availability of treatment options, better reimbursement plan, and RND. Followed by EU- Top 5 countries contribute $X.6 Billion in 2017 and expected to reach $x.5 Billion by 2023.
Developing countries represent a minuscule percentage of the overall market.
The key market participants include GlaxoSmithKline, Roche, Novartis, Pfizer, Bayer, and Sanofi. The growing investment in research and development is driving the companies to innovate, stay market relevant and retain their share. Moreover, there are several startup companies working on stem cell and biologic research, and these companies are considered as strategic assets for merger and acquisition.
Systemic Lupus Erythematosus Drugs Market by Drugs Type (Revenue, Million, 2014 – 2025)
- Intravenous immunoglobulins
Systemic Lupus Erythematosus Drugs Market by Route of Administration (Revenue, Million, 2014 – 2025)
Systemic Lupus Erythematosus Drugs Market by Distribution Channel (Revenue, Million, 2014 – 2025)
- Drug Store
- Specialty Pharmacy
Systemic Lupus Erythematosus Drugs Market Regional Outlook (Revenue, USD Million, 2014- 2025)
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
- South Africa
- Saudi Arabia
Systemic Lupus Erythematosus Drugs Market, Systemic Lupus Erythematosus Drugs Market Analytics, Systemic Lupus Erythematosus Drugs Market Share, Systemic Lupus Erythematosus Drugs Market Research, Systemic Lupus Erythematosus Drugs Market Forecast, Systemic Lupus Erythematosus Drugs Market Insight, Systemic Lupus Erythematosus Drugs Market Trend, Systemic Lupus Erythematosus Drugs Market Value,Systemic Lupus Erythematosus Drugs Market Size, Systemic Lupus Erythematosus Drugs Market Analysis, Systemic Lupus Erythematosus Drugs Market Survey